<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benzylpenicilloyl polylysine (Penicilloyl-polylysine): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benzylpenicilloyl polylysine (Penicilloyl-polylysine): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Benzylpenicilloyl polylysine (Penicilloyl-polylysine): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="16454" href="/d/html/16454.html" rel="external">see "Benzylpenicilloyl polylysine (Penicilloyl-polylysine): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F140308"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pre-Pen</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F140317"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F140310"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a8d5f33c-4cc5-4a08-9d3a-3d82ecf8c43c">Diagnostic aid for detection of penicillin allergy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid for detection of penicillin allergy:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Benzylpenicilloyl polylysine should always be applied first via the puncture technique.<b> Do not administer intradermally to patients who have a positive reaction to the puncture test.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Puncture test:</i> Apply a small drop of the skin test solution using a 22- to 28-gauge needle and make a single shallow puncture of the epidermis through the drop of solution. A positive reaction consists of a pale wheal surrounding the puncture site which develops within 10 minutes and ranges from 5-15 mm or more in diameter (wheal may be surrounded by erythema and variable degrees of itching). If a positive response is evident, the solution should be wiped off immediately. If the puncture test is negative or equivocal (&lt;5 mm wheal, with little or no erythema and no itching) 15 minutes following the puncture test, an intradermal test may be performed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Intradermal test:</i> Using a 0.5-1 mL tuberculin syringe with a <sup>3</sup>/<sub>8</sub> to <sup>5</sup>/<sub>8</sub> inch, 26- to 30-gauge short bevel needle, inject a volume of skin test solution sufficient to raise a small intradermal bleb ~3 mm in diameter intradermally, in duplicate at least 2 cm apart. A control of 0.9% sodium chloride or allergen-diluting solution should be injected at least 5 cm from the antigen test site. Most skin responses to the intradermal test will develop within 5-15 minutes. A response to the skin test is read at 20 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Interpretation of intradermal test: </i></p>
<p style="text-indent:-2em;margin-left:4em;">(-) Negative: No increase in size of original bleb or no greater reaction compared to the control site</p>
<p style="text-indent:-2em;margin-left:4em;">(±) Ambiguous: Wheal only slightly larger than original bleb with or without erythematous flare and slightly larger than control site; OR discordance between duplicate test sites</p>
<p style="text-indent:-2em;margin-left:4em;">(+) Positive: Itching and marked increase in size of original bleb to ≥5 mm. Wheal may exhibit pseudopods and be &gt;20 mm in diameter.</p>
<p style="text-indent:-2em;margin-left:4em;">Control site should be reactionless. If wheal &gt;2-3 mm develops at control site, repeat the test. If same reaction occurs, consultation is necessary.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990028"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987332"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F140311"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F140314"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16454" href="/d/html/16454.html" rel="external">see "Benzylpenicilloyl polylysine (Penicilloyl-polylysine): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a8d5f33c-4cc5-4a08-9d3a-3d82ecf8c43c">Diagnostic aid for detection of penicillin allergy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid for detection of penicillin allergy (penicillin G and benzylpenicillin)</b>: Limited data available for assessment of other beta-lactams and cephalosporins allergy: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Benzylpenicilloyl polylysine should always be applied first via the puncture technique. <b>Do not administer intradermally to patients who have positive reactions to a puncture test.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Puncture scratch test:</i> Apply a small drop of the skin test solution using a 22- to 28-gauge needle and make a single shallow puncture of the epidermis through the drop of solution. A positive reaction consists of a pale wheal surrounding the puncture site which develops within 10 minutes and ranges from 5 to 15 mm or more in diameter (wheal may be surrounded by erythema and variable degrees of itching). If a positive response is evident, the solution should be wiped off immediately. If the puncture test is negative or equivocal (&lt;5 mm wheal, with little or no erythema and no itching) 15 minutes following the puncture test, an intradermal test may be performed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intradermal test:</i> Using a 0.5 to 1 mL tuberculin syringe with a <sup>3</sup>/<sub>8</sub>- to <sup>5</sup>/<sub>8</sub>-inch, 26- to 30-gauge short bevel needle; inject a volume of skin test solution sufficient to raise a small intradermal bleb ~3 mm in diameter intradermally and duplicate at least 2 cm apart. A control of 0.9% sodium chloride or allergen-diluting solution should be injected at least 5 cm from the antigen test site. Most skin responses to the intradermal test will develop within 5 to 15 minutes. A response to the skin test is read at 20 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Interpretation of intradermal test:</i></p>
<p style="text-indent:-2em;margin-left:6em;">(-) Negative: No increase in size of original bleb or no greater reaction compared to the control site.</p>
<p style="text-indent:-2em;margin-left:6em;">(±) Ambiguous: Wheal only slightly larger than original bleb with or without erythematous flare and slightly larger than control site; <b>or</b> discordance between duplicate test sites.</p>
<p style="text-indent:-2em;margin-left:6em;">(+) Positive: Itching and marked increase in size of original bleb to ≥5 mm. Wheal may exhibit pseudopods and be &gt;20 mm in diameter.</p>
<p style="text-indent:-2em;margin-left:6em;">Control site should be reactionless. If wheal &gt;2 to 3 mm develops at control site, repeat the test. If same reaction occurs, consultation is necessary.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090215"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51090216"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F140294"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Erythema, pruritus, urticaria (including local reaction at skin test site)</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Angioedema, hypersensitivity reaction (including anaphylaxis; rare)</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Local inflammation (intense; at skin test site)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea</p></div>
<div class="block coi drugH1Div" id="F140304"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Systemic or marked local reaction to a previous administration of benzylpenicilloyl polylysine skin test; patients with a known severe hypersensitivity to penicillin should not be tested</p></div>
<div class="block war drugH1Div" id="F140291"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergic reactions: Rare systemic allergic reactions, including anaphylaxis, have been associated with penicillin skin testing. Penicillin skin testing should only be performed by skilled medical personnel under direct supervision of a physician, and testing should be performed only in an appropriate healthcare setting prepared for the immediate treatment with epinephrine. To decrease the risk of a systemic allergic reaction, the manufacturer recommends puncture skin testing prior to intradermal testing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Severe penicillin allergy: Patients with a reliable history of a severe life-threatening penicillin allergy, including Stevens-Johnson syndrome or TEN, should <b>NOT</b> receive penicillin skin testing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Histamine H<sub>1</sub> antagonists: Responses to skin testing may be attenuated by concurrent administration of antihistamines. Consider delaying testing until these medications can be withheld to allow time for their effects dissipate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Accuracy: According to the manufacturer, a negative skin test is associated with an incidence of immediate allergic reactions of &lt;5% after penicillin administration and a positive skin test may indicate &gt;50% incidence of allergic reaction occurring after penicillin administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Adequate penicillin skin testing should ideally involve reagents of both the major antigenic determinant (penicilloyl-polylysine) and minor determinants (penicilloate or penilloate). Benzylpenicilloyl polylysine alone does not identify those patients who react to a minor antigenic determinant. The minor determinant mixture (MDM) is not commercially available in the United States; however, diluted penicillin G (concentration: 10,000 units/mL) has been used as a minor determinant for skin testing purposes (Bernstein, 2008). Penicillin skin testing does not predict the occurrence of late reactions (eg, type II, III, IV or idiopathic reactions).</p></div>
<div class="block foc drugH1Div" id="F140299"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. </p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution:</p>
<p style="text-indent:-2em;margin-left:4em;">Pre-Pen®: 6 x 10<sup>-5</sup> M (0.25 mL) </p></div>
<div class="block geq drugH1Div" id="F140287"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323015"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Pre-Pen Intradermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mL (per 0.25 mL): $194.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F140302"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Puncture test: Administer initially by puncture technique on the inner volar aspect of the forearm, followed by an intradermal injection only in patients with a negative reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">Intradermal: Do <b>not</b> administer intradermally to patients with a positive reaction (wheal of 5 to 15 mm or more in diameter) after puncture test. Administer the intradermal test on the upper, outer arm, below the deltoid muscle in the event a severe hypersensitivity reaction occurs and a tourniquet needs to be applied. During the skin test, immediate treatment with epinephrine should also be available.</p></div>
<div class="block admp drugH1Div" id="F52612298"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Puncture test: Administer initially by puncture technique on the inner volar aspect of the forearm; observe 15 minutes for reaction. If negative reaction, follow with an intradermal injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Intradermal test: Do <b>not</b> administer intradermally to patients with a positive reaction to a puncture test (wheal of 5 to 15 mm or more in diameter). Administer the intradermal test on the upper, outer arm, below the deltoid muscle in the event a severe hypersensitivity reaction occurs and a tourniquet needs to be applied. During the skin test, immediate treatment with epinephrine should also be available. Observe 20 minutes for reaction.</p></div>
<div class="block use drugH1Div" id="F140300"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diagnostic aid for detection of penicillin allergy:</b> Adjunct in assessing the risk of administering penicillin (penicillin G or benzylpenicillin) in patients suspected of clinical penicillin hypersensitivity.</p></div>
<div class="block off-label drugH1Div" id="F25721948"><span class="drugH1">Use: Off-Label: Adult</span><p>Adjunct in assessment of hypersensitivity to other beta-lactam antibiotics (penicillins and cephalosporins) to determine the safety of penicillin administration in patients with a history of reaction to cephalosporins</p></div>
<div class="block cyt drugH1Div" id="F13298849"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F140295"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider delaying skin testing until alpha1-agonists are no longer required, or use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihistamines: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F140306"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">The CDC states that penicillin skin testing may be useful in identifying pregnant patients at risk for acute allergic reactions who are diagnosed with syphilis (of any stage) due to a lack of proven alternatives to the use of penicillin in this population (CDC [Workowski 2021]).</p></div>
<div class="block pha drugH1Div" id="F140290"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Benzylpenicilloyl polylysine, a conjugate of the benzylpenicilloyl structural group (hapten) and the poly-l-lysine carrier (protein), is an antigen which reacts with  benzylpenicilloyl IgE antibodies to elicit the release of chemical mediators, thereby producing type I (immediate or accelerated) urticarial reactions in patients hypersensitive to penicillins.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Academy of Allergy, Asthma, and Immunology (AAAAI) Position Statement: “Cephalosporin Administration to Patients With a History of Penicillin Allergy.” Available at http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Cephalosporin-administration-2009.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18431959">
<a name="18431959"></a>Bernstein IL, Li JT, Bernstein DI, et al, “Allergy Diagnostic Testing: An Updated Practice Parameter,” <i>Ann Allergy Asthma Immunol</i>, 2008, 100(3 Suppl 3):1-148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benzylpenicilloyl-polylysine-penicilloyl-polylysine-drug-information/abstract-text/18431959/pubmed" id="18431959" target="_blank">18431959</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention, “Sexually Transmitted Diseases Treatment Guidelines, 2006,”<i> MMWR Recomm Rep</i>, 2009, 55(RR-11):1-94. Available at <a href="https://www.cdc.gov/std/treatment/2006/rr5511.pdf" target="_blank">http://www.cdc.gov/std/treatment/2006/rr5511.pdf</a>.</div>
</li>
<li>
<div class="reference">
                  Pre-Pen (benzylpenicilloyl polylysine) [prescribing information]. Plainville, CT: AllerQuest LLC; received January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benzylpenicilloyl-polylysine-penicilloyl-polylysine-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15949 Version 100.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
